Interrelationships among angiogenesis, proliferation, and apoptosis in the tumor microenvironment during N-methyl-N-nitrosourea androgen-induced prostate carcinogenesis in rats

Carcinogenesis

Volumn 23, Issue 10, 2002, Pages 1701-1711

  Liao, Zhiming ^a   Boileau, Thomas W M ^a   Erdman Jr , John W ^b   Clinton, Steven K ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; METHYLNITROSOUREA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; HISTOPATHOLOGY; HYPERPLASIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DETERMINATION; RAT; STATISTICAL ANALYSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANDROGENS; ANIMALS; ANTIGENS, CD31; APOPTOSIS; CELL DIVISION; MALE; METHYLNITROSOUREA; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR;

EID: 0036799082     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Xie W., Wong YC. and Tsao S.W. (2000) Correlation of increased apoptosis and proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral prostate of the Noble rat. Prostate, 44, 31-39.
2. Shiina H., Igawa M., Shigeno K. et al. (1997) Immunohistochemical analysis of estramustine binding protein with particular reference to proliferative activity in human prostatic carcinoma. Prostate, 32, 49-58.
3. Martin J.J., Martin R., Codesal J., Fraile B., Paniagua R. and Santamaria L. (2001) Cadmium chloride-induced dysplastic changes in the ventral rat prostate: an immunohistochemical and quantitative study. Prostate, 46, 11-20.
4. Bosland M.C. (1992) Animal models for the study of prostate carcinogenesis. J. Cell. Biochem. Suppl., 16H, 89-98.
5. McCormick D.L., Rao K.V., Dooley L., Steele V.E., Lubet R.A., Kelloff G.J. and Bosland M.C. (1998) Influence of N-methyl-N-nitrosourea, testosterone and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Res., 58, 3282-3288.
6. Bosland M.C. and Prinsen M.K. (1990) Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrososurea, 7,12-dimethylbenz(a)anthracene and 3,2′-dimethyl-4-aniinobiophenyl after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res., 50, 691-699.
7. Bosland M.C., Prinsen M.K. and Kroes R. (1983) Adenocarcinomas of the prostate induced by N-nitroso-N-methylurea in rats pretreated with cyproterone acetate and testosterone. Cancer Lett., 18, 69-78.
8. McCormick D.L. and Rao K.V. (1999) Chemoprevention of hormonedependent prostate cancer in the Wistar-Unilever rat. Euro. Urol., 35, 464-467.
9. Kelloff G.J., Sigman C.C., Hawk E.T., Johnson K.M., Crowell J.A. and Guyton K.Z. (2001) Surrogate End-point Biomarkers in Chemopreventive Drug Development. IARC Scientific Publications No. 154, 1ARC, Lyon, pp. 13-26.
10. Hanahan D. and Weinberg R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70.
11. Isaacs J.T. (2000) Apoptosis: translating theory to therapy for prostate cancer. [letter; comment]. J. Natl Cancer Inst., 92, 1367-1369.
12. Vukanovic J. and Isaacs J.T. (1995) Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res. 55, 3517-3520.
13. Folkman J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med, 1, 27-31.
14. Folkman J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285, 1182-1186.
15. Folkman J. (1992) The role of angiogenesis in tumor growth. Cancer Biol. 3, 65-71.
16. Boileau T.W.-M.. Clinton S.K., Liao.Z. and Erdman J.W. Jr (2001) Tomato phytochemicals and diet restriction increase survival of rats with N-methyl-N-nitrosourea (MNU)-testosterone-induced prostate cancer. FASEB J., 15, A618.
17. Reeves P.G. (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr., 123, 1939-1951.
18. Kelman Z. (1997) PCNA: structure, functions and interactions. Oncogene, 14, 629-640
19. Gavrieli Y., Sherman Y. and Ben-Sasson S.A. (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol., 119, 493-501.
20. Kawamura K., Kobayashi Y, Tanaka T., Ikeda R., Fujikawa-Yamamoto K. and Suzuki K. (2000) Intranuclear localization of proliferating cell nuclear antigen during the cell cycle in renal cell carcinoma. Anal. Quant. Cyto. Hist., 22, 107-113.
21. Mukherjee P., Sotnikov A.V., Mangian H.J., Zhou J.-R., Visek W.J. and Clinton S.K. (1999) Energy intake and prostate tumor growth, angiogenesis and vascular endothelial growth factor expression. J. Natl Cancer Inst., 91, 512-523.
22. Montironi R., Galluzzi C.M., Diamanti L., Giannulis l., Scarpelli M. and De Nictolis M. (1993) Proliferating cell nuclear antigen (PCNA) in prostatic invasive adenocarcinoma. Is the proliferation state in the marginal zone of the tumour higher than in the central part? Anticancer Res., 13, 129-132.
23. Montironi R., Galluzzi C.M., Diamanti L., Giannulis l., Pisani E. and Scarpelli M. (1993) Prostatic intra-epithelial neoplasia: expression and location of proliferating cell nuclear antigen in epithelial, endothelial and stromal nuclei. Virch. Archiv. A Pathol. Anat. Histopath., 422, 185-192.
24. Kallakury B.V., Sheehan C.E., Rhee S.J., Fisher H.A., Kaufman R.P. Jr, Rifkin M.D. and Ross J.S. (1999) The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen and p34cdc2. Cancer, 85, 1569-1576.
25. Burger P., Shibata T. and Kleihues P. (1986) The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am. J. Surg. Pathol., 10, 611-617.
26. Sadi M.V. and Barrack E.R. (1991) Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer, 67, 3065-3071.
27. Cheng L., Pisansky T.M., Sebo T.J., Leibovich B.C., Ramnani D.M., Weaver A.L., Scherer B.G., Blute M.L., Zincke H. and Bostwick D.G. (1999) Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin. Cancer Res., 5, 2820-2823.
28. Bostwick D.G., Burke H.B., WheelerT.M. Chung L.W., Bookstein R. Pretlow T.G., Nagle R.B., Montironi R., Lieber M.M. and Veltri R.W. (1994) The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J. Cell. Biochem. Suppl., 19, 283-289.
29. Vacherot F., Azzouz M., Gil-Diez-De-Medina S., Colombel M., De La Taille A., Lefrere Belda M.A., Abbou C.C., Raynaud J.P., and Chopin D.K. (2000) Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr) Permixon in benign prostatic hyperplasia. Prostate, 45, 259-266.
30. Vesalainen S., Lipponen P., Talja M. and Syrjanen K. (1995) Mitotic activity and prognosis in prostatic adenocarcinoma. Prostate, 26, 80-86.
31. Giannulis I., Montironi R., Galluzzi C.M., de Nictolis M. and Diamanti L. (1993) Frequency and location of mitoses in prostatic intraepithelial neoplasia (PIN). Anticancer Res., 13, 2447-2451.
32. Colombel M., Vacherot F., Diez S.G., Fontaine E., Buttyan R. and Chopin D. (1998) Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia. Br. J. Urol., 82, 380-385.
33. Montironi R., Magi Galluzzi C.M., Marina S. and Diamanti L. (1994) Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. J. Cell. Biochem. Suppl., 19, 238-245.
34. Wheeler T.M., Rogers E., Aihara M., Scardino P.T. and Thompson T.C. (1994) Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. J. Cell. Biochem. Suppl., 19, 202-207.
35. Stapleton A.M., Zbell P., Kattan M.W., Yang G., Wheeler T.M., Scardino P.T. and Thompson T.C. (1998) Assessment of the biologic markers p53, Ki-67 and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer, 82, 168-175.
36. Aihara M., Truong L.D., Dunn J.K., Wheeler T.M., Scardino P.T. and Thompson T.C. (1994) Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum. Pathol., 25, 797-801.
37. Glassman D.T., Chon J.K., Borkowski A., Jacobs S.C. and Kyprianou N. (2001) Combined effect of terazosin and finasteride on apoptosis, cell proliferation and transforming growth factor-beta expression in benign prostatic hyperplasia, Prostate, 46, 45-51.
38. Kyprianou N., English H.F. and Isaacs J.T. (1990) Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50, 3748-3753.
39. Kyprianou N. and lsaacs J.T. (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 122, 552-562.
40. English H.F., Kyprianou N. and Isaacs J.T. (1989) Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate, 15, 233-250.
41. Bettencourt M.C., Bauer J.J., Sesterhenn I.A., Connelly R.R. and Moul J.W. (1998) CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J. Urol., 160, 459-465.
42. Brawer M.K., Bigler S.A. and Deering R.E. (1992) Quantitative morphometric analysis of the microcirculation in prostate carcinoma. J. Cell. Biochem. Suppl., 16H, 62-64.
43. Bigler S.A., Deering R.E. and Brawer M.K. (1993) Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum. Pathol., 24, 220-226.
44. Rogatsch H., Hittmair A., Reissigl A., Mikuz G. and Feichtinger H. (1997) Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? J. Pathol., 182, 205-210.
45. Matsushima H., Goto T., HosakaY., Kitamura T. and Kawabe K. (1999) Correlation between proliferation, apoptosis and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer, 85, 1822-1827.
46. Vartanian R.K. and Weidner N. (1995) Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density and epithelial cell proliferation. Lab. Invest., 73, 844-850.
47. Brawer M.K., Deering R.E., Brown M., Preston S.D. and Bigler S.A. (1994) Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer, 73, 678-687.
48. Silberman M.A., Partin A.W., Veltri R.W. and Epstein J.I. (1997) Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer, 79, 772-779.
49. Mydlo J.H., Kral J.G., Volpe M., Axotis C., Macchia R.J. and Pertschuk L.P. (1998) An analysis of microvessel density androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer. Preliminary results and therapeutic implications. Eur Urol., 34, 426-432.
50. Wakui S., Furusato M., Itoh T., Sasaki H., Akiyama A., Kinoshita I., Asano K., Tokuda T., Aizawa S. and Ushigome S. (1992) Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J. Pathol., 168, 257-262.
51. Fregene T.A., Khanuja P.S., Noto A.C., Gehani S.K., Van Egmont E.M., Luz D.A. and Pienta K.J. (1993) Tumor associated angiogenesis in prostate cancer. Anticancer Res., 13, 2377-2382.
52. Weidner N., Carroll P.R., Flax J., Blumenfeld W. and Folkman J. (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol., 143, 401-409.
53. Vesalainen S.L., Lipponen P.K., Talja M.T., Alhava E.M. and Syrjanen K.J. (1994) Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma. Int. J. Cancer, 58, 303-308.
54. Barth P.J., Weingartner K., Kohler H.H. and Bittinger A. (1996) Assessment of the vascularization in prostatic carcinoma: a morphometric investigation. Hum. Pathol., 27, 1306-1310.
55. Lissbrant I.F., Stattin P., Damber J.E. and Bergh A. (1997) Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate, 33, 38-45.
56. Bostwick D., Wheeler T., Miles B., Scardino P., Humphrey P., Hudson M.L.A. and Mahran H. (1996) Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. J. Urol., 155, 554A.
57. Gettman M.T., Bergstralh E.J., Blute M., Zincke H. and Bostwick D.G. (1998) Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology, 51, 79-85.
58. Rubin M.A., Buyyounouski M., Bagiella E., Sharir S., Neugut A., Benson M., de la Taille A., Katz A.E., Olsson C.A. and Ennis R.D. (1999) Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage and clinical outcome. Urology, 53, 542-547.
59. Zhou J.-R., Gugger E.T., Tanaka T., Guo Y., Blackburn G.L. and Clinton S.K. (1999) Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr., 129, 1628-1635.
60. Fukagai T., Namiki T., Namiki H., Carlile R.G., Shimada M. and Yoshida H. (2001) Discrepancies between Gleason scores of needle biopsy and radical prostatectomy specimens. Pathol. Int., 51, 364-370.
61. Nwosu V, Carpten J., Trent J. and Sheridan R. (2001) Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum. Mol. Genet., 10, 2313-8.
62. Brown J. and Giaccia A. (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58, 1408-1416.
63. Folkman J. (1995) Clinical applications of research on angiogenesis. N. Engl. J. Med., 333, 1757-1763